L. Renda

A head‐to‐head comparison of ixekizumab vs. guselkumab in patients with moderate‐to‐severe plaque psoriasis: 12‐week efficacy, safety and speed of response from a randomized, double‐blinded trial

Andrew Blauvelt, Kim Papp, Alice B. Gottlieb et al. · British Journal of Dermatology · 2019 · 172 citations · Full text

Pharmacy, Dermatology, Pharmacotherapy +15

A head‐to‐head comparison of ixekizumab vs. guselkumab in patients with moderate‐to‐severe plaque psoriasis: 24‐week efficacy and safety results from a randomized, double‐blinded trial*

Andrew Blauvelt, C. Leonardi, Boni E. Elewski et al. · British Journal of Dermatology · 2020 · 117 citations · Full text

Medicine, Dermatology, Pharmacotherapy +13

Safety of Ixekizumab Treatment for up to 5 Years in Adult Patients with Moderate-to-Severe Psoriasis: Results from Greater Than 17,000 Patient-Years of Exposure

April W. Armstrong, C. Paul, L. Puig et al. · Dermatology and Therapy · 2019 · 67 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +13

Understanding Treatment Preferences in Patients with Moderate to Severe Plaque Psoriasis in the USA: Results from a Cross-Sectional Patient Survey

David Shrom, Kiran Sikand, L. Renda et al. · Dermatology and Therapy · 2019 · 47 citations · Full text

Medicine, Clinical Sciences, Dermatology +14

Injection Site Reactions in the Federal Adverse Event Reporting System (FAERS) Post-Marketing Database Vary Among Biologics Approved to Treat Moderate-To-Severe Psoriasis

Elsie Grace, Orin M. Goldblum, L. Renda et al. · Dermatology and Therapy · 2019 · 30 citations · Full text

Pharmacy, Dermatology, Pharmacology +16